US FDA approves Lilly’s Cyramza to treat aggressive non-small cell lung cancer
NSCLC occurs when cancer cells form in the lung’s tissues. According to estimates by the National Cancer Institute, about 224,210 individuals in the US are expected to be
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
Under the deal, the two parties will establish scalable processes for manufacturing recombinant adeno-associated viral (rAAV) vector products using current good manufacturing practices (cGMP). The deal will combine
The findings were presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held December 7-11 in Phoenix, Arizona. Dasotraline, a new chemical entity discovered